For: |
Guan YS, La Z, Yang L, He Q, Li P. p53 gene in treatment of hepatic carcinoma: |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v13/i7/985.htm |
Number | Citing Articles |
1 |
Sang‐Gyun Kim, Seung‐Hwan Seo, Ji‐Hun Shin, Jung‐Pyo Yang, Sang Hyung Lee, Eun‐Hee Shin. Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53‐dependent apoptosis and anticancer effect. Journal of Cellular and Molecular Medicine 2019; 23(5): 3234 doi: 10.1111/jcmm.14207
|
2 |
Josiah Cox, Steven Weinman. Mechanisms of doxorubicin resistance in hepatocellular carcinoma. Hepatic Oncology 2016; 3(1): 57 doi: 10.2217/hep.15.41
|
3 |
Lan Sun, Xiaona Zhou, Yanmeng Li, Wei Chen, Shanna Wu, Bei Zhang, Jingyi Yao, Anjian Xu. KLF5 regulates epithelial-mesenchymal transition of liver cancer cells in the context of p53 loss through miR-192 targeting of ZEB2. Cell Adhesion & Migration 2020; 14(1): 182 doi: 10.1080/19336918.2020.1826216
|
4 |
Travis Kidner, Menghua Dai, Prasad S. Adusumilli, Yuman Fong. Advances in Experimental and Translational Research in the Treatment of Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2008; 17(2): 377 doi: 10.1016/j.soc.2008.01.002
|
5 |
Joana D. Amaral, Rui E. Castro, Clifford J. Steer, Cecília M.P. Rodrigues. p53 and the regulation of hepatocyte apoptosis: implications for disease pathogenesis. Trends in Molecular Medicine 2009; 15(11): 531 doi: 10.1016/j.molmed.2009.09.005
|
6 |
Subhra Mandal, Natalia Rosso, Claudio Tiribelli, Giacinto Scoles, Silke Krol. Targeted multicomponent polysomes for high efficiency, simultaneous anti-sense and gene delivery. Soft Matter 2011; 7(19): 9424 doi: 10.1039/c1sm05942d
|
7 |
C Georgiades, N Vallianou, T Argyrakos, A Aristodimou, G Kolovelonis, E Sioula. An unusual case of desmoid tumour presenting as haemorrhagic shock. The Annals of The Royal College of Surgeons of England 2012; 94(2): e81 doi: 10.1308/003588412X13171221588857
|
8 |
Ahmed A. Mohamed, Randa A. Zaghloul, Amr M. Abdelghany, Amal M. El Gayar. Selenium nanoparticles and quercetin suppress thioacetamide‐induced hepatocellular carcinoma in rats: Attenuation of inflammation involvement. Journal of Biochemical and Molecular Toxicology 2022; 36(4) doi: 10.1002/jbt.22989
|
9 |
Juliette Martin, Jean-François Dufour. Tumor suppressor and hepatocellular carcinoma. World Journal of Gastroenterology 2008; 14(11): 1720-1733 doi: 10.3748/wjg.14.1720
|
10 |
Saad Saffo, Tamar H. Taddei. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences 2019; 64(4): 1016 doi: 10.1007/s10620-019-05582-x
|
11 |
Shahida Parveen, Riffat Mehboob, Asad Aslam Khan, Mulazim Hussain Bukhari, Fridoon Jawad Ahmad. Novel strategy to diagnose and grade hepatocellular carcinoma. Natural Science 2013; 5(01): 22 doi: 10.4236/ns.2013.51004
|
12 |
Krisztina Hagymási, Zsolt Tulassay. Epidemiology, risk factors and molecular pathogenesis of primary liver cancer. Orvosi Hetilap 2008; 149(12): 541 doi: 10.1556/oh.2008.28313
|
13 |
Sue Anne Chew, Stefania Moscato, Sachin George, Bahareh Azimi, Serena Danti. Liver Cancer: Current and Future Trends Using Biomaterials. Cancers 2019; 11(12): 2026 doi: 10.3390/cancers11122026
|
14 |
Jelena Krstic, Markus Galhuber, Tim J. Schulz, Michael Schupp, Andreas Prokesch. p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. International Journal of Molecular Sciences 2018; 19(3): 921 doi: 10.3390/ijms19030921
|
15 |
Qingxing Xu, Jiayu Leong, Qi Yi Chua, Yu Tse Chi, Pierce Kah-Hoe Chow, Daniel W. Pack, Chi-Hwa Wang. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013; 34(21): 5149 doi: 10.1016/j.biomaterials.2013.03.044
|
16 |
Qi Xie, Biling Liang, Jing Zhang, Qihua Yang, Xiongfei Gu, Jing Xu, Mingwang Chen. In vivo comparison of transduction efficiency with recombinant adenovirus-mediated p53 in a human colon cancer mouse model by different delivery routes. The Chinese-German Journal of Clinical Oncology 2008; 7(12): 704 doi: 10.1007/s10330-008-0123-y
|
17 |
Razieh Kazemzadeh, Maryam Kheirollahi, Seyed Ali Mard, Akram Ahangarpour, Feryal Savari. Regulatory, diagnostic, and therapeutic roles of microRNAs in chronic liver diseases. Acta Gastro Enterologica Belgica 2024; 87(3): 403 doi: 10.51821/87.2.12965
|
18 |
Tongsen Zheng, Jiabei Wang, Xuan Song, Xianzhi Meng, Shangha Pan, Hongchi Jiang, Lianxin Liu. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. Journal of Cancer Research and Clinical Oncology 2010; 136(10): 1597 doi: 10.1007/s00432-010-0817-8
|
19 |
Zun Mao, Junpeng Mu, Zhixiang Gao, Shile Huang, Long Chen. Biological Functions and Potential Therapeutic Significance of O-GlcNAcylation in Hepatic Cellular Stress and Liver Diseases. Cells 2024; 13(10): 805 doi: 10.3390/cells13100805
|
20 |
Geng Tian, Jiliang Liu, Jie Sui Ruming Zhou, Weihong Chen. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. Anti-Cancer Drugs 2009; 20(5): 389 doi: 10.1097/CAD.0b013e32832a2df9
|
21 |
Kevin Tak-Pan Ng, Chung Mau Lo, Dong Yong Guo, Xiang Qi, Chang Xian Li, Wei Geng, Xiao Bing Liu, Chang Chun Ling, Yuen Yuen Ma, Wai Ho Yeung, Yan Shao, Ronnie Tung-Ping Poon, Sheung Tat Fan, Kwan Man. Identification of Transmembrane Protein 98 as a Novel Chemoresistance-Conferring Gene in Hepatocellular Carcinoma. Molecular Cancer Therapeutics 2014; 13(5): 1285 doi: 10.1158/1535-7163.MCT-13-0806
|
22 |
Xuan Meng, Derek A. Franklin, Jiahong Dong, Yanping Zhang. MDM2–p53 Pathway in Hepatocellular Carcinoma. Cancer Research 2014; 74(24): 7161 doi: 10.1158/0008-5472.CAN-14-1446
|
23 |
Xinli Shi, Jingli Liu, Laifeng Ren, Nan Mao, Fang Tan, Nana Ding, Jing Yang, Mingyuan Li. Nutlin-3 downregulates p53 phosphorylation on serine392and induces apoptosis in hepatocellular carcinoma cells. BMB Reports 2014; 47(4): 221 doi: 10.5483/BMBRep.2014.47.4.146
|
24 |
Xuxian Xiao, Qiongqiong He, Kelong Huang. Novel amino-modified silica nanoparticles as efficient vector for hepatocellular carcinoma gene therapy. Medical Oncology 2010; 27(4): 1200 doi: 10.1007/s12032-009-9359-9
|
25 |
JINGHAN WANG, YONG YU, ZI YAN, ZHENLI HU, LINFANG LI, JIANG LI, XIAOQING JIANG, QIJUN QIAN. Anticancer activity of oncolytic adenoviruses carrying p53 is augmented by 11R in gallbladder cancer cell lines in vitro and in vivo. Oncology Reports 2013; 30(2): 833 doi: 10.3892/or.2013.2511
|
26 |
Shu-Huan Wu, Charng-Cherng Chyau, Jing-Hsien Chen, Shu-Fen Tu, Hui-Hsuan Lin, Fen-Pi Chou. Anti-cancerous effects of Wasabia japonica extract in Hep3B liver cancer cells via ROS accumulation, DNA damage and p73-mediated apoptosis. Journal of Functional Foods 2015; 14: 445 doi: 10.1016/j.jff.2014.12.032
|
27 |
Shu-Yuan Zhang, You-Yong Lu, Zhao-Hui Peng. Recent Advances in Cancer Research and Therapy. 2012; : 215 doi: 10.1016/B978-0-12-397833-2.00010-8
|
28 |
Ji-Wen Cheng, Yi Lv. New progress of non-surgical treatments for hepatocellular carcinoma. Medical Oncology 2013; 30(1) doi: 10.1007/s12032-012-0381-y
|
29 |
Zongqiang Hu, Laibang Li, Ma Li, Xibing Zhang, Yu Zhang, Jianghua Ran, Li Li, Eirini Rigopoulou. miR-21-5p Inhibits Ferroptosis in Hepatocellular Carcinoma Cells by Regulating the AKT/mTOR Signaling Pathway through MELK. Journal of Immunology Research 2023; 2023: 1 doi: 10.1155/2023/8929525
|
30 |
Kang Chen, Xiu Xin, Lipeng Qiu, Wenpan Li, Guannan Guan, Gang Li, Mingxi Qiao, Xiuli Zhao, Haiyang Hu, Dawei Chen. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy. Acta Biomaterialia 2019; 100: 118 doi: 10.1016/j.actbio.2019.09.041
|
31 |
Yoshikuni Inokawa, Kenichi Inaoka, Fuminori Sonohara, Masamichi Hayashi, Mitsuro Kanda, Shuji Nomoto. Molecular alterations in the carcinogenesis and progression of hepatocellular carcinoma: Tumor factors and background liver factors. Oncology Letters 2016; 12(5): 3662 doi: 10.3892/ol.2016.5141
|
32 |
Guo-Dong Yao, Qian Sun, Xiao-Yu Song, Xiao-Xiao Huang, Shao-Jiang Song. Flavan enantiomers from Daphne giraldii selectively induce apoptotic cell death in p53-null hepatocarcinoma cells in vitro. Chemico-Biological Interactions 2018; 289: 1 doi: 10.1016/j.cbi.2018.04.014
|
33 |
Heba Taha, Nourhan Elfar, Hesham Haffez, Zeineb A. Hassan. Raptinal silver nanoparticles: new therapeutic advances in hepatocellular carcinoma mouse model. Naunyn-Schmiedeberg's Archives of Pharmacology 2021; 394(2): 279 doi: 10.1007/s00210-020-01973-4
|
34 |
Zhi Wang, Wenbin Gou, Ming Liu, Wei Sang, Hui Chu, Wei Zhang. Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study. Medical Science Monitor 2015; 21: 3209 doi: 10.12659/MSM.895592
|
35 |
Qi Xie, Bi-Ling Liang, Yan-Heng Wu, Jing Zhang, Ming-Wang Chen, Hong-Yan Liu, Xiong-Fei Gu, Jin Xu. Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene 2012; 499(2): 303 doi: 10.1016/j.gene.2012.02.007
|
36 |
Zhuo Lin, Qian Xu, Dan Miao, Fujun Yu. An Inflammatory Response-Related Gene Signature Can Impact the Immune Status and Predict the Prognosis of Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.644416
|
37 |
Mika Kosaka, Moo Rim Kang, Glen Yang, Long-Cheng Li. Targeted p21WAF1/CIP1 Activation by RNAa Inhibits Hepatocellular Carcinoma Cells. Nucleic Acid Therapeutics 2012; 22(5): 335 doi: 10.1089/nat.2012.0354
|
38 |
Li Qi, Guiqing Li, Peipei Li, Hongwei Wang, Xiaolong Fang, Tongchuan He, Jingjing Li. Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. Genes & Diseases 2024; 11(4): 101155 doi: 10.1016/j.gendis.2023.101155
|
39 |
G. Gonzalez-Aseguinolaza, J. Prieto, R. Hernandez-Alcoceba. Gene therapy of liver cancer: an update. Journal Africain du Cancer / African Journal of Cancer 2011; 3(3): 180 doi: 10.1007/s12558-011-0153-1
|
40 |
Qi Xie, Min-Yi Wu, Ding-Xuan Zhang, Yi-Ming Yang, Bao-Shuai Wang, Jing Zhang, Jin Xu, Wei-De Zhong, Jia-Ni Hu. Synergistic anticancer effect of exogenous wild-type <i>p53</i> gene combined with 5-FU in human colon cancer resistant to 5-FU <i>in vivo</i>. World Journal of Gastroenterology 2016; 22(32): 7342-7352 doi: 10.3748/wjg.v22.i32.7342
|
41 |
Yasmin Ahmed Salama, Amro El-karef, Amal Mohamed El Gayyar, Noha Abdel-Rahman. Beyond its antioxidant properties: Quercetin targets multiple signalling pathways in hepatocellular carcinoma in rats. Life Sciences 2019; 236: 116933 doi: 10.1016/j.lfs.2019.116933
|
42 |
Xuesi Hua, Siyu Xuan, Yangyang Tang, Shilin You, Shang Zhao, Ye Qiu, Yinqing Li, Yongqing Li, Yanping Su, Peng Qu. Progression of oncolytic virus in liver cancer treatment. Frontiers in Oncology 2024; 14 doi: 10.3389/fonc.2024.1446085
|
43 |
Heena B Choudhary, Satish K Mandlik, Deepa S Mandlik. Role of p53 suppression in the pathogenesis of hepatocellular carcinoma. World Journal of Gastrointestinal Pathophysiology 2023; 14(3): 46-70 doi: 10.4291/wjgp.v14.i3.46
|